Literature DB >> 15333684

Identification of patients with high-risk lymph node-negative colorectal cancer and potential benefit from adjuvant chemotherapy.

Luis F Oñate-Ocaña1, Rene Montesdeoca, Carlos M López-Graniel, Vincenzo Aiello-Crocifoglio, Ricardo Mondragón-Sánchez, Mario Cortina-Borja, Roberto Herrera-Goepfert, Cuauhtemoc Oros-Ovalle, Dolores Gallardo-Rincón.   

Abstract

BACKGROUND: Adjuvant chemotherapy is not indicated in lymph node-negative colorectal adenocarcinoma (CRC), even though some cases will present recurrent disease. It is important to identify a subgroup of patients with the highest risk of relapse because of the potential benefit of adjuvant chemotherapy. The objective of this study is to define the prognostic factors and describe a method for the selection of this subgroup.
METHODS: A retrospective cohort of 124 patients with lymph node-negative CRC with complete surgical resection was studied. Cox's proportional hazards model was used to define the prognostic factors associated with CRC-related survival and to develop a method for prediction of recurrence probability.
RESULTS: The cohort included 62 women and 62 men with mean age 55.8 years. The mean follow-up period was 11.7 years. T classification of the primary tumor, differentiation grade, carcinoembryonic antigen level, gender and the presence of neural invasion were significant prognostic factors according to the multivariate analysis (final model P=0.00001). Using risk ratios for these prognostic factors, we defined a high-risk group of 78 patients and a low-risk group of 46 patients with 24 and 5 recurrences, respectively (recurrence rates of 30.8% and 10.9% respectively, P=0.011).
CONCLUSIONS: Using these factors, a prognostic scale was developed to predict high risk of recurrence in cases of completely resected CRC and to identify them as a subgroup of patients with potential benefit of adjuvant chemotherapy.

Entities:  

Mesh:

Year:  2004        PMID: 15333684     DOI: 10.1093/jjco/hyh054

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  9 in total

Review 1.  Prognostic value of perineural invasion in colorectal cancer: a meta-analysis.

Authors:  Yuchong Yang; Xuanzhang Huang; Jingxu Sun; Peng Gao; Yongxi Song; Xiaowan Chen; Junhua Zhao; Zhenning Wang
Journal:  J Gastrointest Surg       Date:  2015-02-07       Impact factor: 3.452

2.  Prognostic factors for patients with stage II colon cancer: results of a prospective study.

Authors:  Chenghai Zhang; Jiabo Di; Beihai Jiang; Ming Cui; Zaozao Wang; Jiadi Xing; Hong Yang; Zhendan Yao; Nan Zhang; Xiangqian Su
Journal:  Int J Colorectal Dis       Date:  2016-01       Impact factor: 2.571

3.  High Expression of DARPP-32 in Colorectal Cancer Is Associated With Liver Metastases and Predicts Survival for Dukes A and B Patients: Results of a Pilot Study.

Authors:  Mario Kopljar; Leonardo Patrlj; Dragan Korolija-Marinic; Matija Horzic; Kristijan Cupurdija; Bore Bakota
Journal:  Int Surg       Date:  2015-02

4.  Perineural invasion is an independent predictor of outcome in colorectal cancer.

Authors:  Catherine Liebig; Gustavo Ayala; Jonathan Wilks; Gordana Verstovsek; Hao Liu; Neeti Agarwal; David H Berger; Daniel Albo
Journal:  J Clin Oncol       Date:  2009-09-08       Impact factor: 44.544

Review 5.  Novel Genetic and Epigenetic Biomarkers of Prognostic and Predictive Significance in Stage II/III Colorectal Cancer.

Authors:  Xiao-Jing Luo; Qi Zhao; Jia Liu; Jia-Bo Zheng; Miao-Zhen Qiu; Huai-Qiang Ju; Rui-Hua Xu
Journal:  Mol Ther       Date:  2020-12-15       Impact factor: 11.454

6.  Review of histopathological and molecular prognostic features in colorectal cancer.

Authors:  Ola Marzouk; John Schofield
Journal:  Cancers (Basel)       Date:  2011-06-23       Impact factor: 6.639

7.  Prognostic classification index in Iranian colorectal cancer patients: Survival tree analysis.

Authors:  Amal Saki Malehi; Fakher Rahim
Journal:  South Asian J Cancer       Date:  2016 Jan-Mar

8.  Overexpression of colorectal cancer oncogene CHRDL2 predicts a poor prognosis.

Authors:  Jian Sun; Xuan Liu; Hong Gao; Long Zhang; Qing Ji; Ziyuan Wang; Lihong Zhou; Yan Wang; Hua Sui; Zhongze Fan; Qi Li
Journal:  Oncotarget       Date:  2017-02-14

9.  Identification of high-risk factors as indicators for adjuvant therapy in stage II colon cancer patients treated at a single institution.

Authors:  Keizo Yamaguchi; Yutaka Ogata; Yoshito Akagi; Kazuo Shirouzu
Journal:  Oncol Lett       Date:  2013-07-01       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.